Supplementary Materials and methods

Patient Samples
Heparinized peripheral blood mononuclear cell (PBMC) samples were collected from 33 CLL patients attending clinics at the Southampton General Hospital, The Royal Berkshire and Royal Wolverhampton NHS trusts (all UK). All samples were obtained following informed consent in accordance with local Ethics Committee approval and the Declaration of Helsinki. The majority of samples were obtained at time of diagnosis prior to treatment for CLL. In the 6 cases where treatment was given, this was at least 12 months prior to sample collection. Tumor IGHV use and homology to germline was determined by aligning the tumor IGHV--D--J rearrangement to the IMGT database (http://imgt.cines.fr/). 1 Mutational status was determined using the conventional 98% homology cut--off. 2 Expression of cell surface CD5 and CD19 were determined as previously described. 3, 4 Surface IgM (sIgM) signaling capacity was determined by measuring the percentage of cells with increased intracellular calcium following stimulation with soluble goat F(ab')2 anti--IgM and using a cut--off value of ≥5% responding cells to define samples as sIgM responsive. 4 PBMCs were cryopreserved and recovered as previously described. 4 
Quantification of reactive oxygen species (ROS)
ROS were quantified using the fluorescent probe CM--H2DCFDA (Life Technologies, Paisley, UK) as described before. 5 Cells were diluted to 1x10 6 cells/ml in complete media and incubated with CM--H2DCFDA (1 µM) for 1 hour at 37 o C in the dark. Cells were then washed twice and resuspended in pre--warmed phosphate buffered saline. Fluorescence was analyzed using a FACS Canto (BD Biosciences, Oxford, UK). Plots were overlaid using FlowJo (v9.5. ROS and CXCR4 expression was determined following gating of live, singlet cells that were positive for both CD19 and CD5.
Statistical Analysis
Statistical comparisons were performed using GraphPad Prism (v6, GraphPad Software Inc., La Jolla, CA, USA) or IBM Statistical Package for the Social Sciences (SPSS) software v.22.0 (Chicago, IL, USA). Time to progression requiring first treatment (TTFT) was defined as the time elapsed from date of diagnosis to date of first treatment. The accepted indications to initiate treatment were based on the National Cancer Institute criteria. 7 Survival analysis was performed by Kaplan--Meier method using log rank statistics to test for significant associations.
Identification of the optimal cut--off value for ROS levels was determined by receiver operating characteristic analysis and Youden's t--test, using treatment as a state variable. 
